Bone Marrow Transplantation - Optimized cyclosporine starting dose may reduce risk of acute GvHD after allogeneic hematopoietic cell transplantation: a single
Cyclosporine is being used with increasing frequency in the prevention and treatment of graft-versus-host disease (GVHD) in patients undergoing allogeneic bone marrow
Cyclosporine is commonly used as an immunosuppressive agent in both solid organ and bone marrow transplant
Gaggero R, Haupt R, Paola Fondelli M, et al
Cyclosporine A (CsA) is commonly used for Graft versus Host Disease (GvHD) prophylaxis at a recommended starting dose of 3 mg/kg/d: Evidence for the
Bone Marrow Transplantation - Impact of antithymocyte globulin usage and risk stratification for posttransplant lymphoproliferative disorders in aplastic anemia
it
Main outcome measures: The means of cyclosporine concentrations were assessed for each patient on a weekly basis during the first 50 days after transplant
19 Hematolgic Malignancies & Bone Marrow Transplant, Department of Medical Oncology, New York Presbyterian Hospital/Weill Cornell Medical Center, New York, New York, USA
In the The first calcineurin inhibitor, cyclosporine (CSA), was introduced, T cell depletion with anti-CD5 immunotoxin in histocompatible bone marrow transplantation
It explains the basic mechanisms of chimerism-based tolerance and provides an update on ongoing clinical tolerance trials
, Okamoto, S
Nephrotoxicity in Cyclosporine is known to increase potassium due to mech-bone marrow transplant Hemoglobin increased in the first 3 months, and trough serum cyclosporine levels were stable
1007/s11864-017-0511-z
Over the past two decades, cyclosporine (CsA) has been widely used as the most important immunosuppressant in kidney transplantation [1,2]
The diagnosis of CIN was considered when a bone marrow transplant recipient on cyclosporine A for GvHD prophylaxis developed clinical symptoms of headache, vomiting, hypertension, tremors, seizures, aphasia, cortical blindness, or disorientation , and had specific electrolyte imbalances and outcomes assessed after the
Acquired aplastic anemia (AA) is a rare, life-threatening bone marrow failure (BMF) disorder that affects patients of all ages and is caused by lymphocyte destruction of early hematopoietic cells
Cyclosporine injection is used in combination with other medicines (eg, steroid medicines) to prevent the body from rejecting a transplanted organ (eg, kidney, liver, or heart)